Clinical Trial

Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel

Study acronym: DoIT_Neck
Recruiting
View on ClinicalTrials.gov →
Summary
Analysis of tumor tissue (which is already available in pathology) and collection of saliva/stool and blood samples, which are obtained as part of a routine collection. These will be evaluated together with the patients' clinical data to identify possible predictors for treatment feasibility, survival, tumor control and potentially increased tumor immunogenicity by docetaxel.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-25.
Status change: Not Yet Recruiting → Recruiting 2026-03-11
Trial Details
NCT Number NCT06947668
Lead Sponsor University of Erlangen-Nürnberg Medical School
Conditions Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of the Hypopharynx, Larynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Enrollment 250 participants
Start Date 2025-05-01
Primary Completion 2030-06-01 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-31